Aduro Biotech, Inc. (NASDAQ:ADRO) EVP Dirk G. Brockstedt sold 10,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $12.18, for a total transaction of $121,800.00. Following the sale, the executive vice president now owns 59,300 shares of the company’s stock, valued at $722,274. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Dirk G. Brockstedt also recently made the following trade(s):
- On Wednesday, May 17th, Dirk G. Brockstedt sold 1,011 shares of Aduro Biotech stock. The stock was sold at an average price of $9.65, for a total transaction of $9,756.15.
Aduro Biotech, Inc. (ADRO) traded up 0.224% during midday trading on Friday, reaching $11.175. 38,561 shares of the company traded hands. Aduro Biotech, Inc. has a 12 month low of $8.75 and a 12 month high of $16.15. The company’s 50-day moving average price is $12.44 and its 200 day moving average price is $10.98. The firm’s market capitalization is $833.79 million.
Aduro Biotech (NASDAQ:ADRO) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.02. The business had revenue of $5.90 million for the quarter, compared to analyst estimates of $3.98 million. Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. The firm’s revenue for the quarter was down 84.9% compared to the same quarter last year. During the same period last year, the company posted $0.03 EPS. On average, equities analysts anticipate that Aduro Biotech, Inc. will post ($1.37) earnings per share for the current year.
Several equities research analysts recently issued reports on the stock. BidaskClub upgraded shares of Aduro Biotech from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. Cowen and Company assumed coverage on shares of Aduro Biotech in a research report on Tuesday, July 18th. They set an “outperform” rating for the company. Zacks Investment Research cut shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. HC Wainwright set a $18.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, Canaccord Genuity set a $30.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a research report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $19.00.
Hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP increased its stake in Aduro Biotech by 9.1% in the first quarter. Wellington Management Group LLP now owns 9,448,529 shares of the biotechnology company’s stock worth $101,571,000 after buying an additional 791,770 shares during the period. Norges Bank acquired a new stake in Aduro Biotech during the fourth quarter worth about $3,266,000. JPMorgan Chase & Co. increased its stake in Aduro Biotech by 283.7% in the second quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock worth $4,244,000 after buying an additional 275,295 shares during the period. Goldman Sachs Group Inc. increased its stake in Aduro Biotech by 330.5% in the first quarter. Goldman Sachs Group Inc. now owns 236,721 shares of the biotechnology company’s stock worth $2,545,000 after buying an additional 181,734 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Aduro Biotech by 762.1% in the first quarter. Renaissance Technologies LLC now owns 181,900 shares of the biotechnology company’s stock worth $1,955,000 after buying an additional 160,800 shares during the period. 35.60% of the stock is owned by hedge funds and other institutional investors.
About Aduro Biotech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
